Society for Immunotherapy of Cancer | 2023 Fellowships
Aim: The Society for Immunotherapy of Cancer’s (SITC) Fellowships program supports the development of early career scientists in the field to cultivate the next generation of cancer immunotherapy experts.
In 2023, 3 fellowship programs are open to international applicants:
SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship: This cancer immunotherapy translational fellowship aims to support an MD, PhD, or combined MD/PhD individual with a vested interest in furthering the research and translation of cancer immunotherapy.
SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship: This clinical fellowship supports an MD or combined MD/PhD degree with a vested interest in furthering the research and translation of immunotherapeutic approaches for the treatment of patients with lung cancer.
SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship: This fellowship provides support to an individual with an MD (or equivalent) or combined MD/PhD degree with a vested interest in furthering the research and translation of adverse events in cancer immunotherapy.
How to Apply: Access the application portal to find precise details for each program. All applicants must be current SITC members, in good standing at time of application.
Deadline: 27 March 2023
Further information
In 2023, 3 fellowship programs are open to international applicants:
SITC-Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship: This cancer immunotherapy translational fellowship aims to support an MD, PhD, or combined MD/PhD individual with a vested interest in furthering the research and translation of cancer immunotherapy.
- Funding: $200,000
- Duration: 2 years
- Eligibility: Hold a PhD or equivalent, currently in a postdoc or comparable position, have a pre-arranged fellowship mentor, and be able to commit 75% effort to the fellowship
SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship: This clinical fellowship supports an MD or combined MD/PhD degree with a vested interest in furthering the research and translation of immunotherapeutic approaches for the treatment of patients with lung cancer.
- Funding: $100,000
- Duration: 1 year
- Eligibility: Hold an MD or combined MD/PhD, currently hold a postdoc or tenure-track position, have a pre-arranged fellowship mentor, and be able to commit 75% effort to the fellowship
SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship: This fellowship provides support to an individual with an MD (or equivalent) or combined MD/PhD degree with a vested interest in furthering the research and translation of adverse events in cancer immunotherapy.
- Funding: $40,000
- Duration: 1 year
- Eligibility: Hold an MD or combined MD/PhD, currently hold a postdoc or tenure-track position, have a pre-arranged fellowship mentor, and be able to commit 75% effort to the fellowship
How to Apply: Access the application portal to find precise details for each program. All applicants must be current SITC members, in good standing at time of application.
Deadline: 27 March 2023
Further information
- More information about the program is available here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free